Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Chemotherapy-induced Peripheral NeuropathyPain, NeuropathicPain Syndrome
Interventions
DRUG

Ozone

Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.

DRUG

Oxygen

Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.

Trial Locations (2)

35016

RECRUITING

Complejo Hospitalario Materno Insular, Las Palmas de Gran Canaria

35019

RECRUITING

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria

All Listed Sponsors
collaborator

Servicio Canario de Salud

OTHER

collaborator

Instituto de Salud Carlos III

OTHER_GOV

collaborator

Red de Investigación en Servicios de Salud en Enfermedades Crónicas

OTHER

collaborator

Fundación DISA, Spain

UNKNOWN

collaborator

Fundación Española del Dolor (FED)

UNKNOWN

lead

Bernardino Clavo, MD, PhD

OTHER